E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if E7070 in combination with idarubicin,
cytarabine, and dexamethasone can help to control the disease in patients with either AML or
high-risk MDS that has relapsed. The safety of the drug combination will also be studied.